Regulatory Briefing
FDA Peptide Review, July 2026: What the PCAC Meeting Could Change
A physician-reviewed briefing on the Pharmacy Compounding Advisory Committee meeting — what's actually on the docket, what "compoundable" means, and what we'd offer if the rules change.
Last updated: June 19, 2026 · Medically reviewed by Kindr Health Clinical Team
The short version. The FDA Pharmacy Compounding Advisory Committee (PCAC) is meeting in July 2026 to review whether several peptides should move off the "do not compound" list. If they do, U.S. 503A pharmacies could legally prepare them under physician prescription. This is not the same as FDA drug approval. No peptide on the docket is being approved as a new drug — only the compounding eligibility is being reconsidered.
What the PCAC is reviewing
The peptides most widely reported as part of the July 2026 docket include:
- BPC-157Pentadecapeptide studied for tendon, ligament, gut and vascular healing.
- CJC-1295 + IpamorelinGHRH analog combined with a selective GH secretagogue.
- SermorelinPreviously FDA-approved (pediatric GH deficiency); now used off-label in adults.
- AOD-9604Modified C-terminal GH fragment studied for fat metabolism.
- Thymosin Alpha-1Immunomodulatory peptide used internationally; restricted in the U.S.
The exact docket may evolve. We'll update this list as the FDA publishes the final meeting agenda.
"Compoundable" vs "FDA-approved" — they're not the same
FDA approval is a drug-level designation: a specific manufacturer submits an NDA or BLA, the FDA reviews efficacy and safety data, and the drug is approved as a finished product (e.g. Ozempic). Compounding eligibility is different — it allows licensed 503A pharmacies to prepare a substance for an individual patient under a physician's prescription. Compounded medications are not FDA-approved drug products. They are a recognized but distinct regulatory pathway.
If a peptide like BPC-157 is moved off the do-not-compound list, it would become legally compoundable. It would not be "FDA-approved." Anyone marketing it as such would be making a regulatory misstatement.
What this could mean for women in perimenopause and menopause
Most peptide marketing today is built around men — recovery, performance, body composition. The women's-health case is different and largely underserved:
- Joint and tendon repair. Estrogen decline accelerates connective-tissue stiffness. Peptides studied for tendon healing (like BPC-157) could complement HRT and resistance training.
- Muscle preservation. Sarcopenia accelerates after menopause. Growth-hormone-axis peptides (sermorelin, CJC/ipamorelin) may support recovery and sleep depth, which support lean mass.
- Sleep quality. GH-axis peptides have the most consistent reported effect on slow-wave sleep — a major perimenopause complaint.
- Skin and hair. GHK-Cu has strong topical dermatology evidence; subcutaneous use is more experimental.
None of these uses replaces hormone therapy. They are adjuncts that may make sense for some patients, only after physician evaluation.
What Kindr Health will and won't do
- Will: Continue to prescribe FDA-approved peptides (semaglutide, tirzepatide, bremelanotide) where indicated.
- Will: Add peptides to our formulary if and only if they become legally compoundable under federal and state pharmacy law and a physician determines them appropriate for a specific patient after evaluation.
- Won't: Sell peptides as retail products, ship without physician evaluation, or market unapproved compounds as "FDA-approved."
- Won't: Prescribe substances that remain on the do-not-compound list or substances we cannot source from a 503A pharmacy in good standing.
Timeline
- 2023–2024: FDA places several peptides on the 503A "do not compound" list pending further review.
- June 2026: FDA publishes preliminary PCAC agenda.
- July 2026: PCAC meets, hears public comment, votes on each substance.
- Post-meeting: FDA issues final guidance — usually within weeks to months of the vote.
Want to be evaluated for a longevity protocol?
Submit a Longevity Consult request. A licensed kindr physician will review your history and labs and let you know which therapies are appropriate for you — today, and as the regulatory landscape evolves.
Request your Longevity Consult →Frequently asked questions
Is BPC-157 FDA-approved?
No. BPC-157 has never been an FDA-approved drug. It was placed on the FDA's 503A "do not compound" list. The July 2026 PCAC meeting may recommend moving it off that list, which would allow legal compounding under physician prescription — but would not constitute FDA approval as a drug product.
What is the PCAC?
The Pharmacy Compounding Advisory Committee is an FDA advisory committee that reviews substances proposed for inclusion on (or removal from) the 503A bulk drug substances list. The FDA is not bound by PCAC recommendations but historically follows them.
When is the meeting?
July 2026. We will update this page within 24 hours of any official decision.
Will kindr Health prescribe these peptides after the ruling?
Kindr Health will offer peptide protocols only for substances that (a) are compoundable under federal and state pharmacy law, and (b) are clinically appropriate for the individual patient based on physician evaluation and laboratory data. We do not and will not sell peptides as retail products.
What about peptides not under review?
Peptides like Selank, Semax, TB-500, and DSIP are not on the July 2026 docket. They remain research-only in the United States and are not prescribed by kindr Health.
Editorial note. This briefing is a clinical-education resource. It does not constitute medical advice or a promise of access. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Compounded medications are not tested by the FDA for safety, effectiveness, or quality. Telehealth services are provided by licensed independent physicians. Last reviewed June 19, 2026.